English
|
Spanish
Supporting oncology professionals through education
Login
Register
The content on this site is intended for healthcare professionals only
Menu
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
News
Latest news
Sign up for news alerts
Submit your news
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Journal information
Journal home
Charges
Editorial board
Founding editors
Editor-in-chief
Contact us
Author information
Submit article
Author guidelines
Editorial policies
Copyright information
Why publish with us
Reviewer information
Reviewer guidelines
Memberships
Videos
Recent videos
Sign up
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Conferences
Latest conferences
Sign up for latest coverage
Submit your event
About
e
cancer
About
e
cancer
Our founders
Funding statement
Contact us
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
Selecting appropriate first line lung cancer therapy
Share :
AACR 2009
18 - 22 Apr 2009
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published:
8 Jul 2009
Views:
15793
Rating:
Save
Rate video
Dr Paul Bunn - University of Colorado, Denver, USA
erlotininb, cetuximab or gefitinib for lung cancer in pill form- less toxic and better tolerated, better survival for patients with EGFR gene mutation.
Categories:
Lung & pleura
Biology
Targeted molecules
Related Videos
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...
25 Mar 2024
Updates on lung cancer from WCLC and ESMO 2023
Dr Luis Raez - Memorial Cancer Institute, Miami, USA
31 Jan 2024
ESMO 2023: Highlights and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
8 Nov 2023
Lung Cancer
Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India
6 Nov 2023
The latest in NSCLC with common EGFR mutations
Dr Alfredo Addeo, Dr Antonio Passaro, Dr Alex Spira and Prof Amanda Tufman
23 Oct 2023
ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC
Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira
22 Oct 2023
Osimertinib plus chemotherapy shows superior results versus osimertinib alone...
Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA
21 Sep 2023
Predictive and prognostic biomarkers for immunotherapy in lung cancer
Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...
7 Jul 2023
ASCO 2023: Lung cancer research highlights
Dr Luis Raez - Memorial Cancer Institute, Miami, USA
26 Jun 2023
More from
e
cancer